Results 251 to 260 of about 1,896,797 (391)
Approval voting and Arrow’s impossibility theorem
François Maniquet, P. Mongin
semanticscholar +1 more source
Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li+12 more
wiley +1 more source
Radiological diagnosis of gallstone sigmoid ileus or coleus: Case report and literature review. [PDF]
Mewa Kinoo S, Naidu V, Maharajh J.
europepmc +1 more source
ORIENTED LIGHT REACTIONS OF THE ARROW WORMSAGITTA CRASSATOKIOKA
Taichiro Goto, Masao Yoshida
openalex +2 more sources
Pullback atherectomy with the Arrow-Fischell atherectomy device [PDF]
John G. Webb+4 more
openalex +1 more source
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi+12 more
wiley +1 more source
THE ROLE OF THE EYE AND CNS COMPONENTS IN PHOTOTAXIS OF THE ARROW WORM,SAGITTA CRASSATOKIOKA
Taichiro Goto, Masao Yoshida
openalex +2 more sources
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza+3 more
wiley +1 more source
Detorsion of Wandering Spleen Causes Significant Hypersplenism Resulting in Thrombocytopenia and Spinal Cord Injury: A Case Report. [PDF]
Innami Y+13 more
europepmc +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source